MicroOrganoSphere (MOS) Drug Screen Pilot Trial in Colorectal Cancer
Completed
Conditions studied: Colorectal Neoplasms
In brief
The purpose of the study is to determine the feasibility of generating sufficient MicroOrganoSpheres (MOS) from a biopsy of a subject's adenocarcinoma of the colon and/or rectum that is metastatic to the liver and completing a drug screen against patient-derived MOS using standard of care drugs used in the treatment of colorectal cancer (oxaliplatin, irinotecan, 5-FU/capecitabine (Xeloda), bevacizumab, panitumumab or cetuximab, trifluridine/tipiracil (Lonsurf), regorafenib and pembrolizumab or nivolumab) in ≤ 14 days.
Key facts
- Study ID
- NCT05189171
- Run by
- Xilis, Inc.
- People needed
- 46
- Starts
- 2022-10-25
- Expected to finish
- 2024-03-18
- Last updated by the study team
- 2024-06-28
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Mayo Clinic — Scottsdale, Arizona, United States
- MedStar Washington Hospital — Washington D.C., District of Columbia, United States
- Mayo Clinic — Jacksonville, Florida, United States
- Mayo Clinic — Rochester, Minnesota, United States
- The University of Tennessee Medical Center — Knoxville, Tennessee, United States
- The University of Texas MD Anderson Cancer Center — Houston, Texas, United States
- Inland Imaging — Spokane, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.